276 related articles for article (PubMed ID: 28651822)
1. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
[TBL] [Abstract][Full Text] [Related]
2. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
3. Refractory Dysphonia Due to Isolated Cricothyroid Muscle Dystonia.
Kraft S; Childes J; Hillel A; Schindler J
J Voice; 2016 Jul; 30(4):501-5. PubMed ID: 26239970
[TBL] [Abstract][Full Text] [Related]
4. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
5. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Namin AW; Christopher KM; Eisenbeis JF
J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
[TBL] [Abstract][Full Text] [Related]
6. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
9. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
11. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
[TBL] [Abstract][Full Text] [Related]
12. Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study.
Di Stadio A; Bernitsas E; Restivo DA; Alfonsi E; Marchese-Ragona R
J Voice; 2019 Jul; 33(4):550-553. PubMed ID: 29650331
[TBL] [Abstract][Full Text] [Related]
13. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Nerurkar NK; Banu TP
J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
15. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
[TBL] [Abstract][Full Text] [Related]
16. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
17. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
18. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
19. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
